Clinical Trials
Dive into the world of clinical trials, where medical innovations are put to the test. Discover ongoing trials, their methodologies, and results. Stay informed about the latest breakthroughs and promising treatments in development. Understand the rigorous process of bringing new therapies to market.
Seagen, Genmab’s Tivdak shows survival benefit in cervical cancer phase 3 trial
Amidst the Federal Trade Commission’s close scrutiny of Pfizer’s monumental $43 billion acquisition of Seagen, there’s a significant breakthrough in ...
Tonix’s long COVID drug fails in pain but shows promise in fatigue
Tonix Pharmaceuticals’ experimental treatment for long COVID with fibromyalgia-like symptoms, TNX-102 SL, did not demonstrate a statistically significant improvement in ...
A Breakthrough Drug for Metastatic Renal Cancer and Dialysis Patients
Oncorena has achieved a significant milestone by administering the first treatment to a patient in their Phase I/II trial of ...
How a New Drug Could Restore Brain Function After Stroke
Addex Therapeutics has made a significant stride in the field of drug discovery and development. Their recent findings, featured in ...
BioNTech and DualityBio Advance Novel HER2-low Breast Cancer Drug to Phase III Trial
BioNTech, the renowned name behind the COVID-19 vaccine breakthrough, is venturing into uncharted territory with its licensed antibody-drug conjugate (ADC), ...
Bavarian Nordic Abandons COVID Booster After Failing to Protect Against New Variants
Bavarian Nordic, a Danish biotech firm, has faced a crossroads that shines a light on the ever-evolving nature of the ...
Tvardi Therapeutics Begins Phase 2 Trial for Novel IPF Treatment
Tvardi Therapeutics, a clinical-stage biopharmaceutical company dedicated to advancing STAT3 inhibitors, has exciting news to share. They’ve initiated the dosing ...
Roche’s Alecensa beats chemo in early-stage lung cancer, following Tecentriq’s lead
With Tecentriq approval, Roche is once again celebrating success, this time in a promising early-stage lung cancer trial starring Alecensa, ...
Mezigdomide, a new oral drug for multiple myeloma, shows ‘modest’ survival benefit in phase 1 trial
A new oral drug for multiple myeloma, mezigdomide, has shown a ‘modest’ survival benefit in a phase 1 trial involving ...
Another Phase 3 flop for FibroGen as DMD drug fails to improve mobility
FibroGen’s troubles continue to mount. The biotech announced its fourth phase 3 failure in four months after the market closed ...
Navigating Peaks and Valleys: Novocure’s Tumor Treating Fields Unveil Divergent Outcomes
In the complex realm of medical breakthroughs, the journey from triumph to setback can be as unpredictable as it is ...
Bayer Advances Parkinson’s Cell Therapy to Phase 2 Trial
A new horizon gleams for Bayer’s quest to conquer Parkinson’s disease through advanced cell therapy. In a significant revelation, the ...
Setbacks Continue: Merck and Eisai’s Ambitious Combo of Keytruda-Lenvima Stumble in Head and Neck Cancer Battle
In a somber development for the pharmaceutical world, Merck and Eisai find themselves facing yet another roadblock on their quest ...
Merck’s Bold Bet: 6-Year Study on Oral PCSK9 Inhibitor Dominates Phase 3 Program
In the ever-evolving landscape of pharmaceutical breakthroughs, Merck & Co. has set its sights on a pioneering endeavor that could ...
Exelixis Celebrates Early End to Cabometyx Trial for Neuroendocrine Tumors due to Remarkable Efficacy
Exelixis, a drug developer, recently halted a cancer trial involving Cabometyx, their tyrosine kinase inhibitor, due to an overwhelming display ...
Roche’s Latest KRAS Data Shows Promise Against Amgen and Mirati, Yet Verdict Remains Uncertain
Roche has presented compelling new data showcasing its KRAS inhibitor, divarasib, as a potential contender against rivals Amgen and Mirati. ...
Pfizer’s Approach to GBS Vaccine Approval Hinges on Immunogenicity Study
Amid the complexities of conducting an efficacy study for a group B streptococcus (GBS) vaccine, Pfizer’s lead vaccine executive is ...
Roche Unveils Interim TIGIT Overall Survival Data Following Unintended Release, Triggering Surge in Stocks
An unexpected revelation has provided the world with a sneak peek into Roche’s highly anticipated TIGIT data. Roche, which had ...
Eli Lilly Sets Example for Roche with Positive Retevmo Results in Thyroid Cancer, Highlighting Feasibility of Trial
Just a few weeks ago, Roche had expressed doubts about the feasibility of a Phase 3 study involving its RET ...
Hutchmed Sets Sights on Chinese Approval for Autoimmune Disorder Drug Following Phase 3 Triumph
Hutchmed, a prominent pharmaceutical player, is gearing up for a significant move as it readies to submit sovleplenib for regulatory ...
Gilead’s Magrolimab Faces Fresh Setback as FDA Issues Partial Clinical Hold
One month after Gilead Sciences made public its decision to halt a myelodysplastic syndromes (MDS) program centered around magrolimab, the ...
Resilient Triumph: Roche and Exelixis’ Tecentriq-Cabometyx Combination Shows Promise in Advanced Prostate Cancer After Past Challenges
After facing setbacks in clinical trials, the combination of Roche’s Tecentriq and Exelixis’ Cabometyx has achieved a breakthrough in treating ...
AI Therapeutics Launches Phase 2 Trial of LAM-001 for Bronchiolitis Obliterans Syndrome Post-Lung Transplant
AI Therapeutics, a forward-looking clinical-stage biopharmaceutical company dedicated to pioneering novel therapies for rare diseases, has announced the initiation of ...
Seagen’s Tukysa Demonstrates Trial Victory in Breast Cancer, Amplifying Roche’s Kadcyla and Significance in Light of Pfizer’s $43B Acquisition
In a strategic move, Pfizer has announced a hefty investment of $43 billion to acquire Seagen, with a keen focus ...
Boehringer’s Obesity Drug with Dual Mechanism Ready for Phase III
Boehringer Ingelheim is forging ahead with its obesity drug candidate, survodutide, moving it into a Phase III program following promising ...
Chimerix’s ONC201 Shows Promise Against H3K27M-Mutant Gliomas
Chimerix, a biopharmaceutical company committed to enhancing and extending the lives of patients grappling with severe diseases, has unveiled significant ...
Pembrolizumab Frontline Use With Lenvatinib Supported in nccRCC
Combining pembrolizumab (Keytruda) with lenvatinib (Lenvima) has showcased enduring effectiveness against tumors in patients with non-clear cell renal cell carcinoma ...
Regeneron’s High-Dose Eylea Demonstrates Persistence as FDA Decision Looms
While awaiting an FDA decision regarding a higher-dose version of Eylea (aflibercept), Regeneron has consistently emphasized the durability of their ...
How Remibrutinib, a Novartis Drug, Can Heal Your Hives
Source – Novartis Novartis has unveiled promising initial outcomes from the Phase III REMIX-1 and REMIX-2 trials assessing the effectiveness ...
Apogee Doses First Patients in Phase I Trial of APG777
Source – Apogee Therapeutics Apogee Therapeutics has embarked on a significant milestone by commencing the dosing of healthy volunteers in ...
